REFERENCES
- Teofili L, Foà R, Giona F, Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients? Haematologica. 2008;93:169–172.
- Teofili L, Giona F, Martini M, Markers of the myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol. 2007;25:1048–1053.
- Ismael O, Shimada A, Hama A, Mutations profile of plocythemia vera and essential thrombocythemia among Japanese children. Pediatr Blood Cancer. 2012;59:530–535.
- Randi ML, Ruzzon E, Tezza F, JAK2 V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia. Aging Clin Exp Res. 2011;23:17–21
- Teofili L, Cenci T, Martini M, The mutant allele burden in children with essential thrombocythemia. Br J Haematol. 2009;145:430–432.
- Scott LM, Rebel VI. JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg? Am J Hematol. 2012;87:1028–1036.
- Kelly K, McMahon C, Langabeer S, Congenital JAK2 V617F polycythemia vera: where does the genotype-phenotype diversity end? Blood. 2008;112:4356–4357.
- Langabeer SE, Haslam K, McMahon C. A prenatal origin of childhood essential thrombocythaemia. Br J Haematol. 2013;163:676–678.
- Anderson LA, Duncombe AS, Hughes M, Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol. 2012;87:175–182.
- Jones AV, Cross NCP. Inherited predisposition to myeloproliferative neoplasms. Ther Adv Hematol 2013;4:237–253.